Jump to Navigation
Home

Main menu

  • Home
  • News
  • Markets Map
  • Sentiments
  • Topics
  • Data
  • Comments
  • Images
  • Blog
  • About

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • Discussions
  • Bridge collapses in Washington state
  • McDonald's Most Caloric Item Ever
  • Bank’s Lobbyists Help in Drafting Bills
  • Hot girls on Auto Shanghai 2013 auto show
  • S&P 500 Snapshot: Rethinking The Risk Of QE Tapering
  • Google Faces Fresh U.S. Scrutiny Over Market Power
  • Twitter Digest: 2013-05-23
  • Wieners to Wunderbar: How Germany got cool
  • Kids' playground made from trash
  • Why youth are key to beating Boko Haram

    Achoo! FDA pulls prescription cold meds

    Thu, 03/03/2011 - 12:25 EDT - Bizmology
    • FDA
    • FDA recalls cold meds
    • health care
    • In the News
    • prescription cold medication
    • RDF10

    Starve a cold? Feed a fever? Or just drink plenty of fluids and feel sorry for yourself.
    Well, this hit close to home since my husband is suffering from the worst cold ever (that might be hyperbole). The FDA just pulled around 500 prescription cold medications, saying they had never been approved for use.
    Seems that the medications or their ingredients predate a 1962 law requiring FDA review. According to the agency, some of the drugs are also listed for use by children but contain the same ingredients as drugs that were labeled as NOT for children in 2008. Other problems include similar names with other products, potentially leading to medication mixups.
    A list of the products can be found here.
    The good news (for me, anyway): I scanned the list and never heard of any of these.  There are still plenty of over-the-counter and prescription drugs out there that treat both garden-variety colds and the worst-cold-ever colds. Which, strangely enough, tend to go away in a week no matter what variety.
    The better news is that the FDA is doing what it is supposed to do, and that is monitor the safety of our food and medications. No doubt the agency will come under fire for this action, since these drugs had been de facto tested on the population for several decades. In a New York Times article, a drug manufacturer made exactly that point:
    “These products have been made for a very long period of time,” said Davis S. Caskey, vice president for pharmaceutical operations at ECR Pharmaceuticals, in Richmond, Va. “They’ve been widely available to the public with minimal side effects.”
    Caskey’s right, of course. But he added that his company would still seek approval for its product. After all, no point in being left out in the cold.
    ~
    Photo by Charles Williams, used under a Creative Commons license.

    • Original article
    • Login or register to post comments
     

    Related

    • Lawmakers Call Out Energy Drink Makers For Inconsistent Labeling, Shady Marketing Practices

      (stevendepolo)

    • Jazz FDA Panel Meeting: Leaning on the Positive Outcome Side

      Kaushik Paul submits:Today, the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee are expected to jointly review the marketing application of Jazz Pharmaceuticals, Inc.’s (JAZZ) JZP-6 (sodium oxybate), designed for the treatment of fibromyalgia syndrome (FMS).

    • A Federal Judge Has Ordered The Morning-After Pill Be Available To Everyone Over-The-Counter

      After a decade-long battle over access to emergency contraception, a federal judge on Friday ordered US regulators to make the morning-after pill available over the counter without limits on age.

    • Acura Pharmaceuticals: A Strong Investment You Can Feel Good About

      By James Hartje: Investing in the future of drug abuse deterrent technology

    • Arena Pharmaceuticals: A Stock For Aggressive Investors

      By Mel Daris:As obesity rates in the United States and other parts of world continue to rise, many biotech and pharmaceutical companies strive to provide medications to curb this epidemic and save lives.

    • Medco Optimistic on New Hepatitis Drugs

      Zacks.com submits: Medco Health Solutions (MHS) is making attempts to curtail costs of treating patients suffering from hepatitis C (HCV). The company’s specialty pharmacy segment, Accredo Health Group, considers patient adherence to the treatment most significant as any contrary behavior could lead to liver cirrhosis and certain cancers.

    • Advisory Votes Against Expanding Use of GSK’s, Merck’s Prostate Drugs: Biotech's Latest Tribulations

      The Burrill Report submits: A U.S. Food and Drug Administration advisory panel has voted against expanding the use of GlaxoSmithKline’s (GSK) Avodart, its treatment for enlarged prostate, to include reducing the risk of prostate cancer in men at risk for the disease. The panel voted 14 to 2 against.

    • Child health at risk from non-prescription drugs: study

      Many parents give their children too large or frequent doses of non-prescription medicines for fever, coughs and colds, putting their health at risk, according to an Australian study released Monday."Many children are being put at risk by parents? over-use of widely-available over the counter medicines for fever, coughs and colds," concluded the study by University of Sydney researchers presented at a conference of the International Pharmaceutical Federation.

    • Child health at risk from non-prescription drugs: study

      Many parents give their children too large or frequent doses of non-prescription medicines for fever, coughs and colds, putting their health at risk, according to an Australian study released Monday."Many children are being put at risk by parents? over-use of widely-available over the counter medicines for fever, coughs and colds," concluded the study by University of Sydney researchers presented at a conference of the International Pharmaceutical Federation.

    • Low-hanging fruit at the FDA

      Perhaps the simplest way to lower costs, speed innovation and even improve health would be to give the FDA the funding it needs to evaluate new treatments and drugs more quickly.

    Latest

    This Simple Email Got Tumblr's 5th Employee His Job
    This Simple Email Got Tumblr's 5th Employee...
    Meg Whitman Isn't Worried About All That Server Market Share Dell Says It's Taking Away From HP (HPQ, DELL)
    Meg Whitman Isn't Worried About All That...

    User login

    • Create new account
    • Request new password
    • Click on the icon to sign in with your social network login or enter your Bullfax.com login

    Our Blog

    • Tata Steel, ECB, China’s car market and European Corporate Tax in Our News for Today 05/24/2013
    • Pandora: the charm might fade away
    • Japanese Market, Indian Rupee, China’s Stocks and Oil Prices in Our Daily Round-Up for 05/23/2013

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 1650.51 -0.29% FTSE: 6645.43 -0.77% Nikk.: 14612.45 0.88% DAX: 8284.12 -0.82% HSI: 22618.67 -0.23% FX: EUR/GBP: 1.1666 USD/EUR: 1.2965 JPY/USD: 101.331 Commodities: Gold: 1386.35

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • Discussions